Table 1

Baseline and clinical characteristics of children with IVR and LP

CharacteristicsIVR groupLP groupTP value
No of eyes/children28/1737/20//
Sex (male/female)8/910/10/0.86*
BGA, weeks30.0±2.629.2±2.5−0.890.38
BW, g1246±3771250±3230.040.97
CGA, weeks37.4±1.636.9±2.0−0.740.46
Age of OCTA examination, years5.4±1.16.3±1.81.850.07
Way of birth (NB/CS)6/1112/8/0.13*
Central foveal VLD13.82±2.9915.64±2.712.560.01
Parafoveal VLD21.71±2.3722.51±1.661.590.12
Foveal VLD20.82±2.3521.73±1.731.800.07
FAZ area (mm2)0.13±0.090.09±0.07−2.010.048
FAZ MI0.62±0.230.51±0.28−1.560.12
Central foveal PD0.25±0.050.28±0.052.820.006
Parafoveal PD0.39±0.040.41±0.031.720.09
Foveal PD0.38±0.040.39±0.031.970.054
CFT (μm)200.7±16.7220.9±22.75.83<0.01
BCVA (Log MAR)0.2±0.10.1±0.1−2.670.01
SER (D)0.31±2.40.13±2.1−0.320.75
  • *X2 test; The remaining indices are the t-test.

  • BCVA, best-corrected visual acuity; BGA, born in gestational age; BW, birth weight; CFT, central foveal thickness; CGA, corrected gestational age at treatment; CS, caesarean section; FAZ, foveal avascular zone; IVR, intravitreal injection of ranibizumab; LogMAR, logarithm of the minimal angle of resolution; LP, laser photocoagulation; MI, Morphological Index; NB, natural birth; OCTA, optical coherence tomography angiography; PD, perfusion density; SER, spherical equivalent refraction; VLD, vessel length density.